Yahoo Finance·2026-01-27 13:38Group 1 - Eli Lilly received FDA Breakthrough Therapy designation for sofetabart mipitecan, aimed at treating adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer [1] - This designation is expected to accelerate development timelines and enhance regulatory engagement, boosting the visibility of Lilly's oncology pipeline [1] - Eli Lilly and Nvidia announced a joint venture to build a new research laboratory in the San Francisco Bay Area, committing $1 billion over the next 5 years [2][3] Group 2 - The new laboratory will utilize Nvidia's Vera Rubin AI chips for advanced research, with the goal of generating high-quality data to train specialized biotech AI models [3] - Researchers from both companies will collaborate at the facility, which aims to reduce the time required to design, discover, and bring new treatments to market [3] - Eli Lilly operates in multiple regions including the US, Europe, China, and Japan, focusing on the discovery, development, and marketing of human pharmaceuticals [4]